🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the effort against increasingly resistant strains of the infection, according to researchers.

A Global Health Concern

Gonorrhoea infections are on the rise worldwide, with data suggesting in excess of 82 million infections per year. Especially elevated rates are observed in Africa and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary development in the context of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted available drugs at this time.”

Public health authorities are deeply concerned about the rise in antibiotic-resistant strains. The WHO has classified it as a "high-priority threat". Recent surveillance showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Receive Authorization

One new antibiotic, also known as a brand name, was approved by the US FDA in mid-December for treating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts believe that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This drug, which is employed against urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to see it through.

“This approval represents a significant shift in the management of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Clinical Trial Results and Worldwide Availability

As per data detailed in a prominent scientific publication, the new drug cured over nine in ten of uncomplicated infections. This places it at an comparable level with the typical regimen, which combines two antibiotics. The study enrolled over 900 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the ability to make available and distribute the drug in numerous developing nations.

Medical professionals on the front lines have shared positive views. The availability of a single-dose, oral treatment such as this is hailed as a "game-changer" for public health efforts. This is deemed essential to reduce the burden of the infection for patients and to prevent the spread of highly drug-resistant gonorrhoea worldwide.